Comprehensive medication guide to {drug} including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Ibsrela (Tenapanor) is an FDA-approved prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) in adults. It belongs to a class of drugs called sodium/hydrogen exchanger 3 (NHE3) inhibitors. Ibsrela is the first and only NHE3 inhibitor approved for IBS-C, offering a unique mechanism of action compared to other treatments on the market.
The active ingredient, Tenapanor Hydrochloride, is also marketed under the brand name Xphozah for a separate indication (hyperphosphatemia in chronic kidney disease).
Ibsrela works by blocking the sodium/hydrogen exchanger 3 (NHE3) transporter located on the surface of intestinal cells. By inhibiting NHE3, Tenapanor reduces sodium absorption from the intestines, which increases fluid secretion into the intestinal lumen. This results in softer, more frequent bowel movements and reduced abdominal pain associated with IBS-C.
Unlike some other IBS-C treatments, Ibsrela acts locally in the gut with minimal systemic absorption, which may contribute to its favorable side effect profile.
Ibsrela (Tenapanor) is a brand-name specialty medication manufactured solely by Ardelyx, Inc. While it is not currently listed on the FDA Drug Shortage Database, many local pharmacies do not routinely stock it due to its specialty status and high cost. Patients often need to use specialty pharmacies or order it through mail-order services. Medfinder can help you locate pharmacies that have Ibsrela in stock near you.
Struggling to find {drug} in stock? We'll call the pharmacies, sit on hold, and find you one that can fill your prescription.
Ibsrela is most commonly prescribed by:
Telehealth consultations are also available for patients who need a prescription. If you're having trouble finding a prescriber, Medfinder can help connect you with providers in your area.
No, Ibsrela is not a controlled substance. It is not classified under any DEA schedule. This means there are no special prescribing restrictions related to controlled substance regulations, and refills can be obtained without additional DEA oversight.
The most commonly reported side effects of Ibsrela include:
Important warning: Ibsrela carries a boxed warning regarding the risk of serious dehydration in pediatric patients. It is contraindicated in children under 6 years of age and should be avoided in children 6 to 12 years old. If you experience severe diarrhea, rectal bleeding, or signs of dehydration, contact your healthcare provider immediately.
If you cannot find or afford Ibsrela, there are several alternative medications used to treat IBS-C:
Talk to your doctor about which alternative may be right for you if Ibsrela is unavailable or not covered by your insurance.
Ibsrela has a relatively favorable drug interaction profile compared to many other medications:
Ibsrela should be taken immediately before meals (breakfast and dinner) for optimal effectiveness. Always inform your doctor about all medications you are taking.
Ibsrela offers a unique treatment option for adults with IBS-C through its first-in-class NHE3 inhibitor mechanism. While the medication is not currently in shortage, its specialty status and high retail cost ($2,000–$2,500 per month) can make it challenging to find at local pharmacies. The good news is that the manufacturer's copay program can bring out-of-pocket costs to as little as $0 for eligible patients with commercial insurance.
If you're struggling to find Ibsrela in stock, Medfinder can help you locate pharmacies near you that carry it. No generic version is currently available, with the earliest generic entry estimated for August 2033.
%2C%20Color%3DOriginal.png)
